Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Aristo Bio-Tech and Lifescience's Return-on-Tangible-Equity or its related term are showing as below:
NSE:ARISTO's Return-on-Tangible-Equity is not ranked *
in the Agriculture industry.
Industry Median: 7.29 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Aristo Bio-Tech and Lifescience (NSE:ARISTO) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Aristo Bio-Tech and Lifescience Return-on-Tangible-Equity Related Terms
Aristo Bio-Tech and Lifescience Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aristo Bio-Tech and Lifescience Return-on-Tangible-Equity Chart
NSE:ARISTO vs CTVA, CF: Return-on-Tangible-Equity Comparison
For the Agricultural Inputs subindustry, Aristo Bio-Tech and Lifescience's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aristo Bio-Tech and Lifescience Return-on-Tangible-Equity vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Aristo Bio-Tech and Lifescience's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Aristo Bio-Tech and Lifescience's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -2.60% mean?
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a Return-on-Tangible-Equity of -2.60% as of Mar. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aristo Bio-Tech and Lifescience and its competitors.
Is Aristo Bio-Tech and Lifescience's Return-on-Tangible-Equity too high?
Aristo Bio-Tech and Lifescience's current Return-on-Tangible-Equity is -2.60%. Overall, Aristo Bio-Tech and Lifescience has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Aristo Bio-Tech and Lifescience's Return-on-Tangible-Equity compare to CTVA and CF?
Aristo Bio-Tech and Lifescience's Return-on-Tangible-Equity of -2.60% can be compared against companies in the Agriculture industry. The industry median Return-on-Tangible-Equity is 7.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Agriculture company?
The median Return-on-Tangible-Equity among Agriculture companies is 7.29, based on 249 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aristo Bio-Tech and Lifescience and its competitors. For the Agriculture industry, the median Return-on-Tangible-Equity is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aristo Bio-Tech and Lifescience's current Return-on-Tangible-Equity is -2.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aristo Bio-Tech and Lifescience stock overvalued right now?
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a current Return-on-Tangible-Equity of -2.60%. The current Return-on-Tangible-Equity is -2.60%. Aristo Bio-Tech and Lifescience's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Aristo Bio-Tech and Lifescience (NSE:ARISTO), the current Return-on-Tangible-Equity is -2.60% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aristo Bio-Tech and Lifescience Business Description
Aristo Bio-Tech and Lifescience Ltd is an agrochemical company. It is mainly engaged in the manufacturing, formulation, supplying, packaging and job work services of various pesticides. The company exports products like Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals.
59GF Score
Get the complete analysis for NSE:ARISTO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ARISTO has been successfully added to your 
